HBOT Conversations:
Dr. Hemal Mehta & Vibrant Health University
Dr. Hemal Mehta, MD is a Medical Director and an Independent Medical Examiner who focuses on pain management through a Regenerative medicine approach. Dr. Mehta is Board Certified in Physical Medicine and Pain Management. He received his Doctor of Medicine Degree from Ross University School of Medicine and completed his residency at East Carolina. He is the Medical Director of Vibrant Health of North Carolina, Tennessee Integrative Pain Institute, and TN Integrative Healthcare: Musculoskeletal and Regenerative Center; additionally, Dr. Mehta is the attending physician at Nashville Regenerative Orthopedics. Dr. Mehta is the 2013 recipient of the Inaugural Patient Appreciation Award at Nashville Academy of Medicine, and the 2004 Research Resident of the Year for East Carolina University. Dr. Mehta has extensive experience with stem cell proliferation, and angiogenesis. He has incorporated Ozone Injection Therapy, PRP (Platelet-Rich Plasma) Injections, Hyperbaric Oxygen Therapy and Regenerative Matrix and Regenerative Medicine Procedures – to name a few – into his integrative wellness & longevity medical practices.
Watch the Podcast
HBOT News Network welcomes back Dr. Hemal V. Mehta, M.D.; Medical Director of Vibrant Health of North Carolina. Dr. Mehta has joined HBOT News Network three times previously, where we focused heavily on the topics of fasting & regenerative medicine – see Dr. Mehta & Fasting, Dr. Mehta & Fasting (Part 2), and Dr. Mehta & Regenerative Medicine.
We are thrilled to have Dr. Mehta return to discuss Vibrant Health University. Vibrant Health University is a new start-up educational program through Vibrant Health. It is a way to help educate, not just the public, but also providers who are interested in performing regenerative therapies, regenerative injections, and providing an alternative to patients that’s not typically available.
Vibrant Health University wants to steer the medical field and general public away from the traditional heavy focus of pharmacology and surgical techniques; and educate people more on the integrative approaches available for regenerative therapies and regenerative treatments. What people can expect from Vibrant Health University (once it gets up and going), is a variety of online programs and podcasts they can watch. Then, if interested further, physicians can choose the option for an in-person educational program where Dr. Mehta or his team can visit the physician’s office (or the physician can visit them) and the physician can then witness live demonstrations, and learn how to do proper procedures for regenerative treatments, while incorporating their protocols into their treatment plans.
The courses at Vibrant Health University will be a structured program with a certification process. Dr. Mehta explains that they are planning to provide different tiers. For example, a lower tier, a medium tier, and a higher tier of education to providers based on their level of expertise, and based on how much knowledge they already have and how much they want to obtain. The ultimate goal of the program is to have the courses accredited by the appropriate certifying boards to count as continuing medical education for physicians.
Dr. Mehta & di Giralomo spend time discussing the importance of physician education, the continued benefits of fasting, and how to gain control of excessive inflammation.
Dr. Mehta remind us of Vibrant Health’s focus — to integrate traditional and non-traditional medicine to give each patient the best outlook and care. Ultimately, integrative medicine is integrating functional medicine and holistic therapies with what we’ve learned through history regarding how the human body works. God gave us everything we need to survive from the beginning of human life. Dr. Mehta ends this segment by explaining through the study of medicine, it’s incredibly difficult to not believe that there is a God or a higher power that has created this body. The human body is made to be able to tolerate all kinds of different injuries, in all kinds of different aspects of life, while adapting to the environment. There is absolutely no other machine that man has ever made that’s even similar to the divine healing capabilities of the human body.
If you’d like to know more about Vibrant Health University, please contact Vibrant Health at www.vibranthcs.com/contact/
Guest

Dr. Hemal Mehta
Subscribe Now, It’s Free!
Recent HBOT News
Changes in vasomotion–effect of hyperbaric oxygen in patients with diabetes Type 2.
Abstract: To investigate vasomotion in diabetic patients who underwent sessions of hyperbaric oxygen (HBO2) therapy. Seventy-one patients with diabetes Type 2 and lower-extremity neuropathy were enrolled in a prospective matched case-control study. A total of 39...
Targeting hypoxia to overcome radiation resistance in head & neck cancers: real challenge or clinical fairytale?
Abstract: Tumor hypoxia is a major cause for failure of therapy in patients with inoperable head and neck cancers. Various anti-hypoxic treatment strategies (e.g. hyperbaric oxygenation, hypoxic cell sensitizers) have been tested in clinical trials in head and neck...
Clinical Trial – Ondansetron vs Ondansetron Plus Dexamethasone for Relieving Intrathecal Morphine Side Effects After C-section
Background: Common adverse side effects related to the use of neuraxial opioids in the
obstetric population include nausea, vomiting, and pruritus. Serotonin (5-HT3) receptor
antagonists, in particular ondansetron, have been identified as possible antipruritic agents.
It was reported that dexamethasone plus ondansetron is more effective than ondansetron for
prevention of postoperative nausea and vomiting but no additional effect on treating
pruritus.
Objectives: The purpose of this study is to compare the effect of prophylactic ondansetron
versus ondansetron plus dexamethasone after cesarean section on pruritus and postoperative
nausea and vomiting (PONV).
Methods: A prospective randomized double blind study that will be conducted between June 2016
and June 2017. Patients will be randomly allocated into two groups. The first group will
receive 4 mg intravenous (IV) ondansetron while the other group will receive 4 mg IV
ondansetron plus 8 mg dexamethasone.
